Fourth-Generation QuantiFERON-TB Gold Plus: What Is the Evidence?
-
- Arena Shafeque
- Department of Pathology, Stanford University School of Medicine, Stanford, California, USA
-
- Jacob Bigio
- Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada
-
- Catherine A. Hogan
- Department of Pathology, Stanford University School of Medicine, Stanford, California, USA
-
- Madhukar Pai
- McGill International TB Centre, Montreal, Quebec, Canada
-
- Niaz Banaei
- Department of Pathology, Stanford University School of Medicine, Stanford, California, USA
-
- Colleen Suzanne Kraft
- editor
Abstract
<jats:p>QuantiFERON-TB Gold Plus (QFT-Plus) is the latest generation of interferon gamma release assays (IGRAs) to receive approval from the U.S. FDA, replacing its predecessor, QuantiFERON-TB Gold In-Tube (QFT-GIT). The novelty of QFT-Plus is that it elicits a response from CD8 T cells, in addition to CD4 T cells, thus collecting a broader response from T-cell subsets than QFT-GIT. It was developed with the aim to improve the detection of latent tuberculosis infection (LTBI), especially among recently exposed contacts, immunocompromised hosts, and young children.</jats:p>
Journal
-
- Journal of Clinical Microbiology
-
Journal of Clinical Microbiology 58 (9), 2020-08-24
American Society for Microbiology
- Tweet
Details 詳細情報について
-
- CRID
- 1360013173017808896
-
- ISSN
- 1098660X
- 00951137
-
- Data Source
-
- Crossref